|
1
|
Poletajew S, Fus L and Wasiutyński A:
Current concepts on pathogenesis and biology of metastatic
osteosarcoma tumors. Ortop Traumatol Rehabil. 13:537–545. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lewis VO: What's new in musculoskeletal
oncology. J Bone Joint Surg Am. 89:1399–1407. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fujiwara T, Katsuda T, Hagiwara K, Kosaka
N, Yoshioka Y, Takahashi RU, Takeshita F, Kubota D, Kondo T,
Ichikawa H, et al: Clinical relevance and therapeutic significance
of microRNA-133a expression profiles and functions in malignant
osteosarcoma-initiating cells. Stem Cells. 32:959–973. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Debebe Z and Rathmell WK: Ror2 as a
therapeutic target in cancer. Pharmacol Ther. 150:143–148. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Geng S, Zhang X, Chen J, Liu X, Zhang H,
Xu X, Ma Y, Li B, Zhang Y, Bi Z, et al: The tumor suppressor role
of miR-124 in osteosarcoma. PLoS One. 9:e915662014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li X, Luo F, Li Q, Xu M, Feng D, Zhang G
and Wu W: Identification of new aberrantly expressed miRNAs in
intestinal-type gastric cancer and its clinical significance. Oncol
Rep. 26:1431–1439. 2011.PubMed/NCBI
|
|
8
|
Luo Z, Dai Y, Zhang L, Jiang C, Li Z, Yang
J, McCarthy JB, She X, Zhang W, Ma J, et al: miR-18a promotes
malignant progression by impairing microRNA biogenesis in
nasopharyngeal carcinoma. Carcinogenesis. 34:415–425. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wu CW, Dong YJ, Liang QY, He XQ, Ng SS,
Chan FK, Sung JJ and Yu J: MicroRNA-18a attenuates DNA damage
repair through suppressing the expression of ataxia telangiectasia
mutated in colorectal cancer. PLoS One. 8:e570362013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Song Y, Wang P, Zhao W, Yao Y, Liu X, Ma
J, Xue Y and Liu Y: MiR-18a regulates the proliferation, migration
and invasion of human glioblastoma cell by targeting neogenin. Exp
Cell Res. 324:54–64. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tao J, Wu D, Li P, Xu B, Lu Q and Zhang W:
microRNA-18a, a member of the oncogenic miR-17-92 cluster, targets
Dicer and suppresses cell proliferation in bladder cancer T24
cells. Mol Med Rep. 5:167–172. 2012.PubMed/NCBI
|
|
12
|
Yanai H, Negishi H and Taniguchi T: The
IRF family of transcription factors: Inception, impact and
implications in oncogenesis. Oncoimmunology. 1:1376–1386. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen YJ, Wu H, Zhu JM, Li XD, Luo SW, Dong
L, Liu TT and Shen XZ: MicroRNA-18a modulates P53 expression by
targeting IRF2 in gastric cancer patients. J Gastroenterol Hepatol.
31:155–163. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sakai T, Mashima H, Yamada Y, Goto T, Sato
W, Dohmen T, Kamada K, Yoshioka M, Uchinami H, Yamamoto Y, et al:
The roles of interferon regulatory factors 1 and 2 in the
progression of human pancreatic cancer. Pancreas. 43:909–916. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nicolini A, Carpi A and Rossi G: Cytokines
in breast cancer. Cytokine Growth Factor Rev. 17:325–337. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dorand RD, Nthale J, Myers JT, Barkauskas
DS, Avril S, Chirieleison SM, Pareek TK, Abbott DW, Stearns DS,
Letterio JJ, et al: Cdk5 disruption attenuates tumor PD-L1
expression and promotes antitumor immunity. Science. 353:399–403.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Amaddeo G, Guichard C, Imbeaud S and
Zucman-Rossi J: Next-generation sequencing identified new oncogenes
and tumor suppressor genes in human hepatic tumors. Oncoimmunology.
1:1612–1613. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xi H and Blanck G: Interferon regulatory
factor-2 point mutations in human pancreatic tumors. Int J Cancer.
87:803–808. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hayashita Y, Osada H, Tatematsu Y, Yamada
H, Yanagisawa K, Tomida S, Yatabe Y, Kawahara K, Sekido Y and
Takahashi T: A polycistronic microRNA cluster, miR-17-92, is
overexpressed in human lung cancers and enhances cell
proliferation. Cancer Res. 65:9628–9632. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Takakura S, Mitsutake N, Nakashima M,
Namba H, Saenko VA, Rogounovitch TI, Nakazawa Y, Hayashi T, Ohtsuru
A and Yamashita S: Oncogenic role of miR-17-92 cluster in
anaplastic thyroid cancer cells. Cancer Sci. 99:1147–1154. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Diosdado B, van de Wiel MA, Terhaar Sive
Droste JS, Mongera S, Postma C, Meijerink WJ, Carvalho B and Meijer
GA: MiR-17-92 cluster is associated with 13q gain and c-myc
expression during colorectal adenoma to adenocarcinoma progression.
Br J Cancer. 101:707–714. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chow TF, Mankaruos M, Scorilas A, Youssef
Y, Girgis A, Mossad S, Metias S, Rofael Y, Honey RJ, Stewart R, et
al: The miR-17-92 cluster is overexpressed in and has an oncogenic
effect on renal cell carcinoma. J Urol. 183:743–751. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
van Haaften G and Agami R: Tumorigenicity
of the miR-17-92 cluster distilled. Genes Dev. 24:1–4. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sarkar S, Balasuriya UB, Horohov DW and
Chambers TM: Equine herpesvirus-1 infection disrupts interferon
regulatory factor-3 (IRF-3) signaling pathways in equine
endothelial cells. Vet Immunol Immunopathol. 173:1–9. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu F, Yu X, Huang H, Chen X, Wang J,
Zhang X and Lin Q: Upregulation of microRNA-450 inhibits the
progression of lung cancer in vitro and in vivo by
targeting interferon regulatory factor 2. Int J Mol Med.
38:283–290. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liang C, Zhang X, Wang HM, Liu XM, Zhang
XJ, Zheng B, Qian GR and Ma ZL: MicroRNA-18a-5p functions as an
oncogene by directly targeting IRF2 in lung cancer. Cell Death Dis.
8:e27642017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
He Y and Yu B: MicroRNA-93 promotes cell
proliferation by directly targeting P21 in osteosarcoma cells. Exp
Ther Med. 13:2003–2011. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jiang R, Zhang C, Liu G, Gu R and Wu H:
MicroRNA-126 inhibits proliferation, migration, invasion and EMT in
osteosarcoma by targeting ZEB1. J Cell Biochem. 118:3765–3774.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lin W, Zhu X, Yang S, Chen X, Wang L,
Huang Z, Ding Y, Huang L and Lv C: MicroRNA-203 inhibits
proliferation and invasion, and promotes apoptosis of osteosarcoma
cells by targeting Runt-related transcription factor 2. Biomed
Pharmacother. 91:1075–1084. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mamane Y, Heylbroeck C, Génin P, Algarté
M, Servant MJ, LePage C, DeLuca C, Kwon H, Lin R and Hiscott J:
Interferon regulatory factors: The next generation. Gene. 237:1–14.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Harada H, Fujita T, Miyamoto M, Kimura Y,
Maruyama M, Furia A, Miyata T and Taniguchi T: Structurally similar
but functionally distinct factors, IRF-1 and IRF-2, bind to the
same regulatory elements of IFN and IFN-inducible genes. Cell.
58:729–739. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Choo A, Palladinetti P, Holmes T, Basu S,
Shen S, Lock RB, O'Brien TA, Symonds G and Dolnikov A: siRNA
targeting the IRF2 transcription factor inhibits leukaemic cell
growth. Int J Oncol. 33:175–183. 2008.PubMed/NCBI
|
